<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PCE- erythromycin ethylsuccinate tablet </strong><br>Arbor Pharmaceuticals, Inc.<br></p></div>
<h1>PCE<span class="Sup">®</span> Tablets <br> (erythromycin particles in tablets)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of PCE tablets and other antibacterial drugs, PCE tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="desc"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PCE tablets (erythromycin particles in tablets) are an antibacterial product containing specially coated erythromycin base particles for oral administration. The coating protects the antibiotic from the inactivating effects of gastric acidity and permits efficient absorption of the antibiotic in the small intestine. PCE tablets are available in two strengths containing either 333 mg or 500 mg of erythromycin base. PCE tablets 500 mg tablets contain no synthetic dyes or artificial colors.</p>
<p>Erythromycin is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccharopolyspora erythraea</span> (formerly <span class="Italics">Streptomyces erythraeus</span>) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. Erythromycin is a white to off-white powder, slightly soluble in water, and soluble in alcohol, chloroform, and ether. Erythromycin is known chemically as (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-<span class="Italics">xylo</span>-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. The molecular formula is C<span class="Sub">37</span>H<span class="Sub">67</span>NO<span class="Sub">13</span>, and the molecular weight is 733.94. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28a270f4-f713-4d88-b83a-f5b5e9b26746&amp;name=pce-01.jpg"></div>
<div class="Section" data-sectionCode="51727-6">
<a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3>PCE 333 mg Tablets</h3>
<p class="First">Cellulosic polymers, citrate ester, colloidal silicon dioxide, D&amp;C Red No. 30, hydrogenated vegetable oil wax, lactose, magnesium stearate, microcrystalline cellulose, povidone, propylene glycol, sodium starch glycolate, stearic acid and vanillin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<h3>PCE 500 mg Tablets</h3>
<p class="First">Cellulosic polymers, citrate ester, colloidal silicon dioxide, crospovidone, hydrogenated vegetable oil wax, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, stearic acid, talc, titanium dioxide and vanillin. PCE 500 mg tablets contain no synthetic dyes or artificial colors.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely bound to plasma proteins. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. Erythromycin crosses the placental barrier, but fetal plasma levels are low. The drug is excreted in human milk. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
<p>In the presence of normal hepatic function, erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral administration, less than 5% of the administered dose can be recovered in the active form in the urine.</p>
<p>The erythromycin particles in PCE tablets are coated with a polymer whose dissolution is pH dependent. This coating allows for minimal release of erythromycin in acidic environments, e.g., stomach. This delivery system is designed for optimal drug release and absorption in the small intestine. In multiple-dose, steady-state studies, PCE tablets have demonstrated rapid and generally adequate drug delivery in both fasting and nonfasting conditions. However, the presence of food results in lower blood levels, and optimal blood levels are obtained when PCE tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals). Bioavailability data are available from Arbor Pharmaceuticals.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Erythromycin acts by inhibition of protein synthesis by binding 50 <span class="Italics">S</span> ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated <span class="Italics">in vitro</span> between erythromycin and clindamycin, lincomycin, and chloramphenicol.</p>
<p>Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae</span> are resistant to erythromycin alone but are susceptible to erythromycin and sulfonamides used concomitantly.</p>
<p>Staphylococci resistant to erythromycin may emerge during a course of erythromycin therapy.</p>
<p>Erythromycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro  </span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#indications">INDICATIONS AND USAGE</a></span> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Gram-positive organisms</h3>
<dl>
<dt> </dt>
<dd>
<span class="Italics">Corynebacterium diphtheriae<br> Corynebacterium minutissimum<br> Listeria monocytogenes</span><br><span class="Italics">Staphylococcus aureu</span>s (resistant organisms may emerge during treatment) <br><span class="Italics">Streptococcus pneumoniae<br> Streptococcus pyogenes</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Gram-negative organisms</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span><br> Legionella pneumophila<br> Neisseria gonorrhoeae</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Other microorganisms</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Chlamydia trachomatis<br> Entamoeba histolytica<br> Mycoplasma pneumoniae<br> Treponema pallidum<br> Ureaplasma urealyticum</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<p class="First">The following <span class="Italics">in vitro</span> data are available, <span class="Bold"><span class="Underline">but their clinical significance is unknown</span></span>.</p>
<p>Erythromycin exhibits <span class="Italics">in vitro</span> minimal inhibitory concentrations (MIC's) of 0.5 µg/mL or less against most (≥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of erythromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.5"></a><p></p>
<h3>Gram-positive organisms</h3>
<dl>
<dt> </dt>
<dd>Viridans group streptococci</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.6"></a><p></p>
<h3>Gram-negative organisms</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Moraxella catarrhalis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.7"></a><p></p>
<h3>Susceptibility Tests</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.7.1"></a><p></p>
<h4>Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's). These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1,2</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of erythromycin powder. The MIC values should be interpreted according to the following criteria:</p>
<p>For <span class="Italics">Staphylococcus</span> spp:</p>
<a name="table1"></a><table width="65%">
<colgroup>
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
</colgroup>
<thead><tr class="First Last">
<th align="center">MIC (µg/mL)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 0.5</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">1-4</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">≥ 8</td>
<td class="Botrule" align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>For <span class="Italics">Streptococcus</span> spp. and <span class="Italics">Streptococcus pneumoniae</span>:</p>
<table width="65%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">MIC (µg/mL)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 0.25</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">0.5</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥ 1</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard erythromycin powder should provide the following MIC values:</p>
<a name="table2"></a><table width="65%">
<colgroup>
<col align="center" valign="top" width="60%">
<col align="center" valign="top" width="40%">
</colgroup>
<thead><tr class="First Last">
<th align="center">Microorganism</th>
<th align="center">MIC (µg/mL)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>ATCC is a registered trademark of the American Type Culture Collection</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">S. aureus ATCC<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> 29213</td>
<td align="center">0.25-1</td>
</tr>
<tr>
<td align="center">E. faecalis ATCC 29212</td>
<td align="center">1-4</td>
</tr>
<tr class="Last">
<td align="center">S. pneumoniae ATCC 49619</td>
<td align="center">0.03-0.12</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.7.2"></a><p></p>
<h4>Diffusion Techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 15-µg erythromycin to test the susceptibility of microorganisms to erythromycin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15-µg erythromycin disk should be interpreted according to the following criteria:</p>
<p>For <span class="Italics">Staphylococcus</span> spp:</p>
<a name="table3"></a><table width="65%">
<colgroup>
<col align="center" valign="top" width="60%">
<col align="center" valign="top" width="40%">
</colgroup>
<thead><tr class="First Last">
<th align="center">Zone Diameter (mm)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥ 23</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">14-22</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">≤ 13</td>
<td class="Botrule" align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>For <span class="Italics">Streptococcus</span> spp. and <span class="Italics">Streptococcus pneumoniae</span>:</p>
<table width="65%">
<colgroup>
<col align="center" valign="top" width="60%">
<col align="center" valign="top" width="40%">
</colgroup>
<thead><tr class="First Last">
<th align="center">Zone Diameter (mm)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥ 21</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">16-20</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤ 15</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques.  Interpretation involves correlation of the diameter obtained in the disk test with the MIC for erythromycin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 15-µg erythromycin disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="table4"></a><table width="65%">
<colgroup>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="40%">
</colgroup>
<thead><tr class="First Last">
<th align="left">Microorganism</th>
<th align="center">Zone Diameter (mm)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">S. aureus ATCC 25923</td>
<td align="center">22-30</td>
</tr>
<tr class="Last">
<td align="left">S. pneumoniae ATCC 49619</td>
<td align="center">25-30</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of PCE tablets and other antibacterial drugs, PCE tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>PCE tablets are indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the diseases listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> of mild to moderate degree caused by <span class="Italics">Streptococcus pyogenes</span>; <span class="Italics">Streptococcus pneumoniae</span>; <span class="Italics">Haemophilus influenzae</span> (when used concomitantly with adequate doses of sulfonamides, since many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.)</p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> of mild to moderate severity caused by <span class="Italics">Streptococcus pyogenes</span> or <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> caused by <span class="Italics">Listeria monocytogenes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> due to <span class="Italics">Mycoplasma pneumoniae</span>.</p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mild to moderate severity caused by <span class="Italics">Streptococcus pyogenes</span> or <span class="Italics">Staphylococcus aureus</span> (resistant staphylococci may emerge during treatment).</p>
<p><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> (whooping <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) caused by <span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span>. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> in exposed susceptible individuals.</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> due to <span class="Italics">Corynebacterium diphtheriae</span>, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.</p>
<p>Erythrasma: In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Corynebacterium minutissimum</span>.</p>
<p>Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> caused by <span class="Italics">Entamoeba histolytica</span> (oral erythromycins only). Extraenteric <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> requires treatment with other agents.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">Neisseria gonorrhoeae:</span> Erythrocin<span class="Sup">®</span> Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">N. gonorrhoeae</span> in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> before receiving erythromycin as treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> and a follow-up serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> after 3 months.</p>
<p>Erythromycins are indicated for treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Chlamydia trachomatis:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> of the newborn, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> of infancy, and urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults due to <span class="Italics">Chlamydia trachomatis</span>.</p>
<p>When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.</p>
<p>Primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> caused by <span class="Italics">Treponema pallidum</span>. Erythromycin (oral forms only) is an alternative choice of treatment for primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> in patients allergic to the penicillins. In treatment of primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, spinal fluid should be examined before treatment and as part of the follow-up after therapy.</p>
<p>Legionnaires' Disease caused by <span class="Italics">Legionella pneumophila</span>. Although no controlled clinical efficacy studies have been conducted, <span class="Italics">in vitro</span> and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Prophylaxis</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Prevention of Initial Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h3>
<p class="First">Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> (treatment of Streptococcus pyogenes <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the upper respiratory tract e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>).<span class="Sup">4</span> Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.2"></a><p></p>
<h3>Prevention of Recurrent Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h3>
<p class="First">Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span> (for the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>).<span class="Sup">4</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="train"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Erythromycin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this antibiotic.</p>
<p>Erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine or dihydroergotamine. (See <span class="Bold"><a href="#drugint">PRECAUTIONS – Drug Interactions</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurring in patients receiving oral erythromycin products.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>QT Prolongation</h2>
<p class="First">Erythromycin has been associated with prolongation of the QT interval and infrequent cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported. Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> in Pregnancy</h2>
<p class="First">There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent <span class="product-label-link" type="condition" conceptid="434279" conceptname="Congenital syphilis">congenital syphilis</span>. Infants born to women treated during pregnancy with oral erythromycin for early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should be treated with an appropriate penicillin regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including PCE tablets, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile,</span> and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with simvastatin, lovastatin, and atorvastatin; and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see <span class="Bold"><a href="#drugint">PRECAUTIONS – Drug Interactions</a></span>).</p>
<p>There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine. This interaction is potentially life-threatening, and may occur while using both drugs at their recommended doses (see <span class="Bold"><a href="#drugint">PRECAUTIONS – Drug Interactions</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. (See package insert for lovastatin.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="prec"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing PCE tablets in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Since erythromycin is principally excreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#warn">WARNINGS</a></span>.)</p>
<p>Exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and new onset of symptoms of <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> has been reported in patients receiving erythromycin therapy.</p>
<p>There have been reports of infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis, seven neonates (5%) developed symptoms of non-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">bilious vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. A possible doseresponse effect was described with an absolute risk of IHPS of 5.1% for infants who took erythromycin for 8-14 days and 10% for infants who took erythromycin for 15-21 days.<span class="Sup">5</span> Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> or neonatal Chlamydia trachomatis <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding occurs.</p>
<p>Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, erythromycin should be discontinued and appropriate therapy instituted.</p>
<p>When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>Observational studies in humans have reported cardiovascular malformations after exposure to drug products containing erythromycin during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including PCE tablets should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When PCE tablets are prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by PCE tablets or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="drugint"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Theophylline</h3>
<p class="First">Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.</p>
<p>There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin serum concentrations of approximately 35%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline could result in subtherapeutic concentrations of erythromycin.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.</p>
<p>Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. </p>
<p>There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with oral anticoagulants may be more pronounced in the elderly.</p>
<p>Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system (CYP3A). Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving erythromycin.</p>
<p>The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.1"></a><p></p>
<h4>Ergotamine/dihydroergotamine</h4>
<p class="First">Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated (see <span class="Bold"><a href="#train">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.2"></a><p></p>
<h4>Triazolobenzodiazepines (such as triazolam and alprazolam) and related benzodiazepines</h4>
<p class="First">Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.3"></a><p></p>
<h4>HMG-CoA Reductase Inhibitors</h4>
<p class="First">Erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin). Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking these drugs concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.4"></a><p></p>
<h4>Sildenafil (Viagra)</h4>
<p class="First">Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. Reduction of sildenafil dosage should be considered. (See Viagra package insert.)</p>
<p>There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methyl-prednisolone, cilostazol, vinblastine, and bromocriptine.</p>
<p>Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. (See <span class="Bold"><a href="#train">CONTRAINDICATIONS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<p class="First">In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</p>
<p>Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT<span class="Sub">c</span> interval prolongation, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, have been observed. (See <span class="Bold"><a href="#train">CONTRAINDICATIONS</a></span>.) In addition, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported rarely with concomitant administration of terfenadine and erythromycin.</p>
<p>There have been post-marketing reports of drug interactions when erythromycin was co-administered with cisapride, resulting in QT prolongation, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, most likely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported. (See <span class="Bold"><a href="#train">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<h3>Colchicine</h3>
<p class="First">Colchicine is a substrate for both CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Erythromycin is considered a moderate inhibitor of CYP3A4. A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin. If co-administration of colchicine and erythromycin is necessary, the starting dose of colchicine may need to be reduced, and the maximum colchicine dose should be lowered. Patients should be monitored for clinical symptoms of colchicine toxicity (see <a href="#warn">WARNINGS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Erythromycin interferes with the fluorometric determination of urinary catecholamines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term oral dietary studies conducted with erythromycin stearate in rats up to 400 mg/kg/day and in mice up to about 500 mg/kg/day (approximately 1-2 fold of the maximum human dose on a body surface area basis) did not provide evidence of tumorigenicity. Erythromycin stearate did not show genotoxic potential in the Ames, and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assays or induce chromosomal aberrations in CHO cells. There was no apparent effect on male or female fertility in rats treated with erythromycin base by oral gavage at 700 mg/kg/day (approximately 3 times the maximum human dose on a body surface area basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">There is no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base by oral gavage at 350 mg/kg/day (approximately twice the maximum recommended human dose on a body surface area) prior to and during mating, during gestation, and through weaning. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or embryotoxicity was observed when erythromycin base was given by oral gavage to pregnant rats and mice at 700 mg/kg/day and to pregnant rabbits at 125 mg/kg/day (approximately 1-3 times the maximum recommended human dose).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of erythromycin on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Erythromycin is excreted in human milk. Caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#indications">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>. (See <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Elderly patients may be more susceptible to development of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> than younger patients. (See <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<p>Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See <span class="Bold"><a href="#drugint">PRECAUTIONS - Drug Interactions</a></span>).</p>
<p>PCE 333 MG Tablets contain 0.5 mg (0.02 mEq) of sodium per individual dose.</p>
<p>PCE 500 MG Tablets do not contain sodium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatic dysfunction and/or abnormal liver function test results may occur. (See <span class="Bold"><a href="#warn">WARNINGS</a></span>.)</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment. (See <span class="Bold"><a href="#warn">WARNINGS</a></span>.)</p>
<p>Erythromycin has been associated with QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. (See <span class="Bold"><a href="#warn">WARNINGS</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred. <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> ranging from mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> to <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely.</p>
<p>There have been reports of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> coincident with erythromycin use.</p>
<p>There have been rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>There have been isolated reports of reversible <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> occurring chiefly in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients receiving high doses of erythromycin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, erythromycin should be discontinued. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures should be instituted.</p>
<p>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">In most patients, PCE tablets are well absorbed and may be dosed orally without regard to meals. However, optimal blood levels are obtained when either PCE 333 mg or PCE 500 mg tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The usual dosage of PCE tablets are one 333 mg tablet every 8 hours or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Children</h2>
<p class="First">Age, weight, and severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> this dosage may be doubled but should not exceed 4 g per day.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> of the upper respiratory tract (e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>), the therapeutic dosage of erythromycin should be administered for at least ten days.</p>
<p>The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> for the prevention of recurring attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> in patients allergic to penicillin and sulfonamides.<span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> of the Newborn Caused by Chlamydia trachomatis</h2>
<p class="First">Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks.<span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> of Infancy Caused by Chlamydia trachomatis</h2>
<p class="First">Although the optimal duration of therapy has not been established, the recommended therapy is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> During Pregnancy Due to Chlamydia trachomatis</h2>
<p class="First">Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of erythromycin by mouth four times a day or two erythromycin 333 mg tablets orally every 8 hours on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12 hours, one 333 mg tablet orally every 8 hours or 250 mg by mouth four times a day should be used for at least 14 days.<span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.6"></a><p></p>
<h2>For adults with uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by Chlamydia trachomatis, when tetracycline is contraindicated or not tolerated</h2>
<p class="First">500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least 7 days.<span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.7"></a><p></p>
<h2>For patients with nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated</h2>
<p class="First">500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least seven days.<span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.8"></a><p></p>
<h2>Primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span></h2>
<p class="First">30 to 40 g given in divided doses over a period of 10 to 15 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.9"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic Inflammatory Disease</span> Caused by N. gonorrhoeae</h2>
<p class="First">500 mg Erythrocin Lactobionate-I.V. (erythromycin lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of erythromycin base orally every 12 hours, or 333 mg of erythromycin base orally every 8 hours for 7 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.10"></a><p></p>
<h2>Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.10.1"></a><p></p>
<h3>Adults</h3>
<p class="First">500 mg every 12 hours, 333 mg every 8 hours or 250 mg every 6 hours for 10 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.10.2"></a><p></p>
<h3>Children</h3>
<p class="First">30 to 50 mg/kg/day in divided doses for 10 to 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.11"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span></h2>
<p class="First">Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.12"></a><p></p>
<h2>Legionnaires' Disease</h2>
<p class="First">Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PCE tablets (erythromycin particles in tablets) are supplied as unscored, ovaloid tablets in the following strengths and packages.</p>
<p>333 mg, pink-speckled white (imprinted with PCE):</p>
<table width="60%">
<col align="left" valign="top" width="30%">
<col align="right" valign="top" width="70%">
<tbody class="Headless"><tr class="First Last">
<td align="left">Bottles of 60</td>
<td align="right">(<span class="Bold">NDC</span> 24338-112-60).</td>
</tr></tbody>
</table>
<p>500 mg, white (imprinted with EK):</p>
<table width="60%">
<col align="left" valign="top" width="30%">
<col align="right" valign="top" width="70%">
<tbody class="Headless"><tr class="First Last">
<td align="left">Bottles of 100</td>
<td align="right">(<span class="Bold">NDC</span> 24338-114-13).</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Recommended Storage</h2>
<p class="First">Store below 86°F (30°C).</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 7th ed. Approved Standard, CLSI Document M07-A7, Vol. 26(2). CLSI, Wayne, PA, Jan. 2006.</li>
<li>Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 18th Informational Supplement, CLSI Document M100-S18, Vol 28(1). CLSI, Wayne, PA, Jan. 2008.</li>
<li>Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests, 9th ed. Approved Standard CLSI Document M02-A9, Vol. 26(1). CLSI, Wayne, PA, Jan. 2006.</li>
<li>Committee on <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association: Prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>. Circulation. 78(4):1082-1086, October 1988.</li>
<li>Honein, M.A., et. al.: Infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> after <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis with erythromycin: a case review and cohort study. The Lancet 1999; 354 (9196):2101-5.</li>
<li>Data on file, Arbor Pharmaceuticals.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">03-A549-R1, Revised January, 2012</p>
<p>Arbor Pharmaceuticals<br>Atlanta, GA 30328</p>
<p>www.arborpharma.com</p>
<p>(Nos. 3389, 6290)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 333 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 24338-112-60<br>60 Tablets</p>
<p><span class="Bold">PCE<span class="Sup">®</span></span><br><span class="Bold">333</span><span class="Bold"> mg<br>TABLETS</span></p>
<p>ERYTHROMYCIN<br>PARTICLES<br>IN TABLETS</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">arbor</span>™<br>PHARMACEUTICALS, LLC.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 333 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28a270f4-f713-4d88-b83a-f5b5e9b26746&amp;name=pce-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 24338-114-13<br>100 Tablets</p>
<p><span class="Bold Italics">PCE</span><span class="Sup">®</span><br><span class="Bold Italics">500</span><span class="Italics"> mg<br>TABLETS</span></p>
<p><span class="Italics">erythromycin<br>particles in tablets</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">arbor</span>™<br>PHARMACEUTICALS, LLC.<br></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28a270f4-f713-4d88-b83a-f5b5e9b26746&amp;name=pce-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PCE 		
					</strong><br><span class="contentTableReg">erythromycin ethylsuccinate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24338-112</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN ETHYLSUCCINATE</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN</td>
<td class="formItem">333 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>powdered cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium starch glycolate type a corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>vanillin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pink-speckled white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Ovaloid) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PCE</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24338-112-60</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050611</td>
<td class="formItem">10/05/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PCE 		
					</strong><br><span class="contentTableReg">erythromycin ethylsuccinate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24338-114</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN ETHYLSUCCINATE</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>powdered cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>vanillin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">EK</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24338-114-13</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050611</td>
<td class="formItem">10/05/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Arbor Pharmaceuticals, Inc.
							(781796417)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2742a78f-022f-4c97-be6f-f97c4a7c4527</div>
<div>Set id: 28a270f4-f713-4d88-b83a-f5b5e9b26746</div>
<div>Version: 6</div>
<div>Effective Time: 20140123</div>
</div>
</div> <div class="DistributorName">Arbor Pharmaceuticals, Inc.</div></p>
</body></html>
